BioCentury | Mar 8, 2017
Company News

Management tracks

...Monique Champagne president and CEO. She was VP of clinical research and regulatory affairs at Telesta Therapeutics Inc....
BioCentury | Dec 16, 2016
Regulation

Blip or dip?

...Xa inhibitors Manufacturing Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) Qapzola apaziquone Non-muscle invasive bladder cancer (NMIBC) Efficacy Telesta Therapeutics Inc....
BioCentury | Nov 2, 2016
Company News

Telesta, ProMetic deal

...of Telesta for C$0.14 per share, payable in ProMetic stock (see BioCentury, Sept. 5 ). Telesta Therapeutics Inc....
...Belleville, Ontario ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF), Laval, Quebec Business: Cancer Nora Weintraub ProMetic Life Sciences Inc. Telesta Therapeutics Inc....
BioCentury | Oct 3, 2016
Finance

Dressed in black

...reduce annualized operating expenses by $4.2M. 8/2/16 Telesta Therapeutics Inc. (TSX:TST; Pink:BNHLF) NA $30.7 NA 6/30/16 Profitable Telesta...
...complete response letter for a BLA for MCNA to treat high-risk non-muscle invasive bladder cancer. Telesta...
...wall-DNA complex (MCC). In late August, ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) agreed to acquire Telesta...
BioCentury | Sep 5, 2016
Company News

Telesta, Prometic deal

...ProMetic will acquire Telesta for C$0.14 per share, payable in ProMetic shares. The deal values Telesta...
...on 302.5 million shares outstanding on May 9. The price represents a 100% premium to Telesta’s...
...deal was announced. The deal is slated to close in early November. In early August, Telesta...
BioCentury | Aug 8, 2016
Company News

Telesta cancer news

...expenditure controls” to focus on contractual obligations and licensing or acquiring clinical or near-clinical therapeutics. Telesta...
...March 31 and 32 at June 30. Ipsen Group (Euronext:IPN, Boulogne-Billancourt, France) will return to Telesta...
...risk non-muscle invasive bladder cancer outside of North America, South Africa, South Korea and Japan. Telesta...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

...a phosphorodiamidate morpholino oligomer (PMO) that induces skipping of exon 51 in dystrophin mRNA. 3/8/16 Telesta Therapeutics Inc....
...from its Montreal, Quebec, manufacturing facility. In February, FDA issued a complete response letter to Telesta...
...III trial of the mycobacterial cell wall-DNA complex. For fiscal 1H15 ended Dec. 31, 2015, Telesta...
BioCentury | Mar 21, 2016
Company News

Telesta cancer news

...came from Telesta’s Montreal manufacturing facility. In February, FDA issued a complete response letter to Telesta...
...FDA asked for an additional Phase III trial of the mycobacterial cell wall-DNA complex (MCC). Telesta...
...FDA to gain clarity on the letter (see BioCentury, Feb. 8). At Dec. 31, 2015, Telesta...
BioCentury | Feb 8, 2016
Clinical News

MCNA regulatory update

...FDA issued a complete response letter to Telesta for a BLA for MCNA to treat high-risk...
...bladder cancer (NMIBC) in patients who have failed first-line treatment with bacille Calmette-Guerin (BCG) therapy. Telesta...
...commercialize MCNA for NMIBC (see BioCentury, Nov. 23, 2015). Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Telesta Therapeutics Inc....
BioCentury | Jan 11, 2016
Finance

Sowing season

...Orphan Biovitrum AB (SSE:SOBI) Orfadin nitisinone oral suspension Hereditary tyrosinemia type I PDUFA date 2Q16 Telesta Therapeutics Inc....
Items per page:
1 - 10 of 180
BioCentury | Mar 8, 2017
Company News

Management tracks

...Monique Champagne president and CEO. She was VP of clinical research and regulatory affairs at Telesta Therapeutics Inc....
BioCentury | Dec 16, 2016
Regulation

Blip or dip?

...Xa inhibitors Manufacturing Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) Qapzola apaziquone Non-muscle invasive bladder cancer (NMIBC) Efficacy Telesta Therapeutics Inc....
BioCentury | Nov 2, 2016
Company News

Telesta, ProMetic deal

...of Telesta for C$0.14 per share, payable in ProMetic stock (see BioCentury, Sept. 5 ). Telesta Therapeutics Inc....
...Belleville, Ontario ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF), Laval, Quebec Business: Cancer Nora Weintraub ProMetic Life Sciences Inc. Telesta Therapeutics Inc....
BioCentury | Oct 3, 2016
Finance

Dressed in black

...reduce annualized operating expenses by $4.2M. 8/2/16 Telesta Therapeutics Inc. (TSX:TST; Pink:BNHLF) NA $30.7 NA 6/30/16 Profitable Telesta...
...complete response letter for a BLA for MCNA to treat high-risk non-muscle invasive bladder cancer. Telesta...
...wall-DNA complex (MCC). In late August, ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) agreed to acquire Telesta...
BioCentury | Sep 5, 2016
Company News

Telesta, Prometic deal

...ProMetic will acquire Telesta for C$0.14 per share, payable in ProMetic shares. The deal values Telesta...
...on 302.5 million shares outstanding on May 9. The price represents a 100% premium to Telesta’s...
...deal was announced. The deal is slated to close in early November. In early August, Telesta...
BioCentury | Aug 8, 2016
Company News

Telesta cancer news

...expenditure controls” to focus on contractual obligations and licensing or acquiring clinical or near-clinical therapeutics. Telesta...
...March 31 and 32 at June 30. Ipsen Group (Euronext:IPN, Boulogne-Billancourt, France) will return to Telesta...
...risk non-muscle invasive bladder cancer outside of North America, South Africa, South Korea and Japan. Telesta...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

...a phosphorodiamidate morpholino oligomer (PMO) that induces skipping of exon 51 in dystrophin mRNA. 3/8/16 Telesta Therapeutics Inc....
...from its Montreal, Quebec, manufacturing facility. In February, FDA issued a complete response letter to Telesta...
...III trial of the mycobacterial cell wall-DNA complex. For fiscal 1H15 ended Dec. 31, 2015, Telesta...
BioCentury | Mar 21, 2016
Company News

Telesta cancer news

...came from Telesta’s Montreal manufacturing facility. In February, FDA issued a complete response letter to Telesta...
...FDA asked for an additional Phase III trial of the mycobacterial cell wall-DNA complex (MCC). Telesta...
...FDA to gain clarity on the letter (see BioCentury, Feb. 8). At Dec. 31, 2015, Telesta...
BioCentury | Feb 8, 2016
Clinical News

MCNA regulatory update

...FDA issued a complete response letter to Telesta for a BLA for MCNA to treat high-risk...
...bladder cancer (NMIBC) in patients who have failed first-line treatment with bacille Calmette-Guerin (BCG) therapy. Telesta...
...commercialize MCNA for NMIBC (see BioCentury, Nov. 23, 2015). Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Telesta Therapeutics Inc....
BioCentury | Jan 11, 2016
Finance

Sowing season

...Orphan Biovitrum AB (SSE:SOBI) Orfadin nitisinone oral suspension Hereditary tyrosinemia type I PDUFA date 2Q16 Telesta Therapeutics Inc....
Items per page:
1 - 10 of 180